Seer, Inc. (SEER)
Market Cap | 146.42M |
Revenue (ttm) | 16.62M |
Net Income (ttm) | -93.90M |
Shares Out | 63.94M |
EPS (ttm) | -1.49 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 220,543 |
Open | 2.28 |
Previous Close | 2.27 |
Day's Range | 2.26 - 2.32 |
52-Week Range | 2.25 - 8.78 |
Beta | 1.42 |
Analysts | Sell |
Price Target | 8.25 (+260.26%) |
Earnings Date | Nov 7, 2023 |
About SEER
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and b... [Read more]
Financial Performance
In 2022, Seer, Inc.'s revenue was $15.49 million, an increase of 134.14% compared to the previous year's $6.62 million. Losses were -$92.97 million, 30.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SEER stock is "Sell." The 12-month stock price forecast is $8.25, which is an increase of 260.26% from the latest price.
News

Seer to Participate in Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management...

Seer Reports Second Quarter 2023 Financial Results
Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies

Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

Seer to Report Second Quarter 2023 Financial Results on August 8, 2023
REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center
Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific commu...

Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer's Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer's Proteograph X...

Seer Reports First Quarter 2023 Financial Results
Grew revenue 22% year-over-year with continued growth in installed base and an increasing number of customer presentations and publications REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Seer,...

Seer to Report First Quarter 2023 Financial Results on May 9, 2023
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will repor...

Seer's Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression
Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Peptide-level insights from deep, un...

Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook
Grew revenue 134% and increased instruments shipped 129% year over year Grew revenue 134% and increased instruments shipped 129% year over year

Seer to Present at the Cowen 43rd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report...

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference
REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS
Creates a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis to support drug and diagnostic development HUNTSVILLE, Ala. , Dec. 14, 2022 /PRN...

Seer's Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist
Annual award from The Scientist celebrates transformative products like Seer's Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible Annual award from The Scientist celebrate...

Seer Reports Third Quarter 2022 Financial Results
Proteograph utility is demonstrated as market interest continues to build with multiple studies underway Proteograph utility is demonstrated as market interest continues to build with multiple studies...

Seer to Report Third Quarter 2022 Financial Results on November 8, 2022
REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...

Seer to Participate in the Morgan Stanley Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome
Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins Published results highlight how the combination ...

Seer Reports Second Quarter 2022 Financial Results
Company launches novel proteogenomics workflow with the Proteograph™ Analysis Suite 2.0, further demonstrates the power of its technology with new customer data, and advances key partnerships Company ...

Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0
Scalable, high-resolution, sample-specific analysis brings genomics and proteomics together to enable novel biological insights with the click of a button Scalable, high-resolution, sample-specific an...

Seer to Report Second Quarter 2022 Financial Results on August 9, 2022
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report finan...

Seer Reports First Quarter 2022 Financial Results
Demonstrated solid commercial traction with continued robust interest in the Proteograph Product Suite Demonstrated solid commercial traction with continued robust interest in the Proteograph Product ...

Seer to Present at the BofA Securities 2022 Healthcare Conference
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company w...

Seer to Report First Quarter Financial Results on May 4, 2022
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...